# Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease

> **NCT07258641** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 30 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)
- Crohn Disease (CD)

## Interventions

- **DRUG:** 25mg adalimumab-680LT and 15/25 mg risankizumab-800CW
- **DRUG:** Adalimumab-680LT 25mg
- **DRUG:** Risankizumab-800CW 15 mg/25 mg

## Key facts

- **NCT ID:** NCT07258641
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07258641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07258641, "Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07258641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*